These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251 [TBL] [Abstract][Full Text] [Related]
5. Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. Kim G; Kim H; Kim KN; Son JI; Kim SY; Tamura T; Chang N J Alzheimers Dis; 2013; 33(3):853-62. PubMed ID: 23042212 [TBL] [Abstract][Full Text] [Related]
6. Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 22(4):1223-30. PubMed ID: 20930303 [TBL] [Abstract][Full Text] [Related]
8. Stem cell factor plasma levels are decreased in Alzheimer's disease patients with fast cognitive decline after one-year follow-up period: the Pythia-study. Laske C; Sopova K; Hoffmann N; Stransky E; Hagen K; Fallgatter AJ; Stellos K; Leyhe T J Alzheimers Dis; 2011; 26(1):39-45. PubMed ID: 21593573 [TBL] [Abstract][Full Text] [Related]
9. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606 [TBL] [Abstract][Full Text] [Related]
10. Decreased serum angiogenin level in Alzheimer's disease. Kim YN; Kim DH Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):116-20. PubMed ID: 22449478 [TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851 [TBL] [Abstract][Full Text] [Related]
12. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084 [TBL] [Abstract][Full Text] [Related]
13. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622 [TBL] [Abstract][Full Text] [Related]
14. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. Smits LL; Pijnenburg YA; Koedam EL; van der Vlies AE; Reuling IE; Koene T; Teunissen CE; Scheltens P; van der Flier WM J Alzheimers Dis; 2012; 30(1):101-8. PubMed ID: 22366769 [TBL] [Abstract][Full Text] [Related]
15. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Susanto TA; Pua EP; Zhou J; J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 and risk of late-onset Alzheimer's disease: findings from a family study. van Exel E; Eikelenboom P; Comijs H; Deeg DJ; Stek ML; Westendorp RG Neurobiol Aging; 2014 Mar; 35(3):725.e7-10. PubMed ID: 24054991 [TBL] [Abstract][Full Text] [Related]
18. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377 [TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282 [TBL] [Abstract][Full Text] [Related]
20. The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. D'Onofrio G; Panza F; Seripa D; Sancarlo D; Paris F; Cascavilla L; Urbano M; Gravina C; Fontana A; Solfrizzi V; Pellegrini F; Pilotto A Int J Geriatr Psychiatry; 2011 Oct; 26(10):1062-70. PubMed ID: 21905100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]